In Vivo 11β-Hydroxysteroid Dehydrogenase Inhibition in Posaconazole-Induced Hypertension and Hypokalemia | Zendy

George R. Thompson | Zendy; Diana Chang | Zendy; Rebecca Wittenberg | Zendy; Ian McHardy | Zendy; Alison Semrad | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In Vivo 11β-Hydroxysteroid Dehydrogenase Inhibition in Posaconazole-Induced Hypertension and Hypokalemia

Author(s) -

George R. Thompson,

Diana Chang,

Rebecca Wittenberg,

Ian McHardy,

Alison Semrad

Publication year - 2017

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00760-17

Subject(s) - posaconazole , hypokalemia , medicine , in vivo , pharmacology , azole , mineralocorticoid , endocrinology , biology , itraconazole , antifungal , dermatology , aldosterone , genetics

We describe a case of apparent mineralocorticoid excess (AME) secondary to posaconazole therapy and suggest the biochemical mechanism. Clinical and laboratory investigation confirmed 11β-hydroxysteroid dehydrogenase inhibition and withholding therapy led to a resolution of all clinical and laboratory abnormalities. Posaconazole was later restarted at a lower dose and prevented recurrence of this syndrome. Additional studies are necessary to determine the frequency of posaconazole-induced AME and whether other azole antifungals can be associated with this phenomenon.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research